| CASE SERIES |
|
| Year : 2023 | Volume
: 55
| Issue : 4 | Page : 263-265 |
A case series on tofacitinib-induced weight gain
Kanisha Shah1, Dhaiwat Shukla2, Manish Patel2, Supriya Malhotra1
1 Department of Pharmacology, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat, India
2 Department of Medicine, VS General Hospital, Ahmedabad, Gujarat, India
Correspondence Address:
Supriya Malhotra
Department of Pharmacology, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijp.ijp_158_23
Janus kinase inhibitor tofacitinib belongs to a group of targeted synthetic disease-modifying anti-rheumatic drugs, also known as small molecule inhibitors. They are oral drugs with a novel strategy to treat inflammatory diseases. The major concern with the use of these drugs is a high risk for infections and other potential side effects. Here, we have focused on reporting one of the rare side effects of tofacitinib, weight gain. We have reported six cases of tofacitinib-induced weight gain in patients of ankylosing spondylitis, rheumatoid arthritis, and vasculitis.
[FULL TEXT] [PDF]*
|
